India-based life-sciences company Zydus Lifesciences Limited announced on Tuesday that its wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates, has entered into a strategic partnership with Formycon AG (FSE: FYB), a biosimilar developer based in Germany.
The agreement covers the exclusive licensing and supply of checkpoint inhibitor FYB206, a biosimilar of Keytruda (pembrolizumab), in the USA and Canada market.
Formycon will develop, register, produce and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates, will be responsible for the commercialisation of FYB206 in the defined territories.
The BLA application is expected to be submitted to the US FDA soon and is aimed at making immunotherapy affordable and accessible to patients in need.
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Mirum Pharmaceuticals to acquire Bluejay Therapeutics for HDV treatment
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
J & D Pharmaceuticals' investigational therapy for HCC receives US FDA Orphan Drug Designation
FDA lifts partial clinical hold on Vanda Pharmaceuticals' tradipitant for motion sickness
TransThera publishes clinical results from US-based Phase 2 trial of tinengotinib in CCA
Hope Medicine wins FDA Fast Track Designation for HMI-115 in endometriosis
MED-EL cochlear implant FDA approved for children 7 months and older